Reportedly, The U.S. Department of Health and Human Services has put Johnson & Johnson (JNJ) in charge of the Emergent BioSolutions facility in Baltimore that ruined 15 million doses of its COVID-19 vaccine. The incident has stopped British drugmaker AstraZeneca Plc from using the facility and will now only produce a single-dose Johnson & Johnson COVID-19 vaccine.
J&J assumed full responsibility for the plant, restating that it will deliver 100 million doses by the end of May. The company has already strengthened its control over Emergent BioSolutions’ work to avoid any further quality lapses.
The decision came in after the workers at the Emergent BioSolutions plant mixed ingredients for the J&J and AstraZeneca vaccines, as per reports. Emergent is a manufacturing partner to both AstraZeneca and Johnson & Johnson.
The government’s decision to have the facility make only the J&J single-dose vaccine is meant to avoid future mix-ups. It also raises concerns for U.S. officials that the mishap at the Emergent plant could dampen public confidence in the vaccines. The mix-up has delayed future shipments of Johnson & Johnson doses in the U.S. while the FDA is investigating the incident.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.